[educational]Elamipretide — a mitochondrial-targeted synthetic tetrapeptide that penetrates to the inner mitochondrial membrane and binds/stabilizes cardiolipin → stable electron transport chain → ↑ATP, ↓ROS (breaks the mito-dysfunction vicious cycle). Now FDA-approved for Barth syndrome (168-wk trial: +30–40% muscle strength, ~50% heart-function markers) — its only approved use. — SS-31 deep dive
Mechanisms
Evidence
[educational] Off-label (mostly preclinical): dementia/cognitive decline & TBI (mouse), chronic kidney disease (mouse models + a human phase-2 in renal-artery stenting), diabetes/insulin resistance (mouse), chronic fatigue/long COVID (anecdotal + ↑ATP), anti-aging healthspan (mouse). Cardiolipin declines with age; benefit appears from ~human-50 onward (no effect in young mice). — SS-31 deep dive
Anecdotes
[anecdote-bb] 5 mg ×5 days/wk × ~3 wks gave no obvious subjective benefit atop the mito stack; best-claimed use is pre-surgery (raising mitochondrial function/density before extensive procedures). — Anabolic Roundtable ~01:49–01:53
[educational] Longevity #6 (honorable mention) — provides structural (cardiolipin) support to mitochondria vs MOTS-C’s training effect; has more human safety data. A tossup with MOTS-C. — Longevity Top-5
[educational] For longevity the creator picks MOTS-C over SS-31 because MOTS-C benefits mice of all ages (trains mitochondria) whereas SS-31 mainly provides structural (cardiolipin) support that’s needed with aging — though SS-31 has more human safety data. — MOTS-C deep dive
Physician protocols
[protocol] SubQ (no oral — 4 aa too large for di/tripeptide gut transporters). Human trials 40 mg/day (extreme-dysfunction populations); for age-related use start 5–10 mg/day, titrate by 5 mg to max 40 (cost ~$1/mg). Daily dosing (cleared <24 h; structural role). Anti-aging cycle 1 month on / 1 off; use in 50s+ or when mito labs show dysfunction. — SS-31 deep dive
Practical notes
[educational]Notably clean safety — extensive human data (Barth 168 wk, myopathy/AMD/heart-failure trials) with only injection-site reactions; no receptors/signaling → no cancer, immune, or mitochondrial-overstress concern (unlike MOTS-C); little tolerance/tachyphylaxis. — SS-31 deep dive